PT  - JOURNAL ARTICLE
AU  - Unlu, Ismet
AU  - Diniz, Gulden
AU  - Komurcuoglu, Berna
AU  - Gayaf, Mine
AU  - Gokce, Tumay
AU  - Karadogan, Ilker
AU  - Akcay, Cimen
TI  - Comparison of curative and palliative radiotherapy efficacy in unresectable advanced non-small cell lung cancer patients with or without metastasis
DP  - 2006 Jun 01
TA  - Saudi Medical Journal
PG  - 849--853
VI  - 27
IP  - 6
4099  - http://smj.org.sa/content/27/6/849.short
4100  - http://smj.org.sa/content/27/6/849.full
SO  - Saudi Med J2006 Jun 01; 27
AB  - OBJECTIVE: To evaluate the efficacy of curative and palliative radiotherapy in inoperable advanced non-small cell lung cancer (NSCLC) patients with a performance status (PS) equal or greater than 2, and to compare the therapy effect on survival with or without metastatic disease.METHODS: From January 1998 through December 2004, 797 patients with inoperable stage III and IV NSCLC were treated with radiotherapy alone because of older age, cardiovascular disease, insufficient respiratory reserve or general frailty. Radical radiotherapy, consisting of approximately 60 Gy, given in 30 fractions was performed in 363 (45.5 %) of these patients. The other 434 patients (54.5%) were treated with palliative dose radiotherapy. Conventional follow-up of the patients was conducted at Izmir Oncology Center. All results were evaluated statistically.RESULTS: Seven hundred and sixty-three patients (95.7%) were male. The mean age was 61.02 years (± 9.678), ranging from 30-88 years. The prominent histology was squamous cell carcinoma (70.7%). Sixty-five patients (8.2%) have been staged IIIA, 419 (52.6%) IIIB, and 313 (39.3%) IV. The median follow up of patients was 274.19 days. One-year survival rate was 37%, and 2-year survival rate was 11% in the radical radiotherapy group, while these rates were 20% and 5% in the others.CONCLUSION: Although radical thoracic radiotherapy for metastatic NSCLC has not been adopted universally, this study shows that curative radiotherapy for the primary tumor provides additional survival benefit in patients with metastatic disease compared with palliative radiotherapy. This result raises the question of whether treatment with radical radiotherapy alone might be the most beneficial and cost-effective treatment of advanced stage NSCLC.